According to reports, Eli LillyThe company has deployed the world's largest and most powerful AI pharmaceutical factory, which uses NVIDIA- basedDGX supercluster based on Blackwell architecture.

In terms of drug discovery, AI can identify potential drug targets and assist in drug molecule design by analyzing massive biomedical data. Using machine learning algorithms, AI can predict the structure, activity, and toxicity of compounds, quickly screen out candidate drugs with clinical potential, and shorten drug development time. According to TouBao Research Institute, from 2019 to 2023, the scale of China's AI pharmaceutical market will increase from 70 million yuan to 410 million yuan, with a compound annual growth rate of 57.4%. It is estimated that from 2024 to 2028, the market size will increase from 730 million yuan to 5.86 billion yuan, with a compound annual growth rate of 68.5%. Soochow SecuritiesThe research report points out that the AI ​​pharmaceutical industry is gradually entering a short period of stability after rapid growth, and is expected to usher in the next or even the third round of explosive growth.

According to the Cailianshe theme database, among the relevant listed companies:

Hongbo PharmaceuticalThe forward-looking AI pharmaceutical layout continues to empower customers with new drug research and development. As of the end of 2024, the company's independently developed CADD/AIDD technology platform has served 40 customers and 80 new drug projects.

Chengdu PioneerIn collaboration with Tencent AILab, we have jointly designed and developed a molecular skeleton transition algorithm that can generate molecules with similar activity but different skeletons while keeping the molecular side chains unchanged.

Source：https://finance.eastmoney.com/a/202510293547693619.html